| Nov 13 |
Spero Therapeutics Q3 2024 Earnings Preview
|
| Nov 6 |
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
|
| Nov 6 |
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
|
| Oct 30 |
Spero’s stock slides after antibiotic flops in Phase II trial
|
| Oct 30 |
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
|
| Oct 29 |
Spero to cut 39% of workforce on failed study, stock plunges 20%
|
| Oct 29 |
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
|
| Oct 27 |
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
|
| Oct 16 |
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
|
| Oct 2 |
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
|
